E-therapeutics Plc (ETXPF) Stock
E-therapeutics Plc is a UK-based company focused on drug discovery. The core of its work involves a sophisticated computational platform that employs in-silico screening and unique network models to identify and predict which compounds or biological targets can effectively alter relevant biological processes.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cash Flow (USD)
Valuation & Return Ratios
Peer Comparison
About E-therapeutics Plc
E-therapeutics Plc is a UK-based company focused on drug discovery. The core of its work involves a sophisticated computational platform that employs in-silico screening and unique network models to identify and predict which compounds or biological targets can effectively alter relevant biological processes. Furthermore, the company is advancing an RNA interference (RNAi) platform designed for highly specific gene silencing. Founded in 2001, E-therapeutics Plc operates from its headquarters in London, United Kingdom.
E-therapeutics Plc is headquartered in GB.
E-therapeutics Plc (ETXPF) stock trades at $0.13 with a market capitalization of $75.96M. The stock is valued at a price-to-earnings (P/E) ratio of -4.71, price-to-book of 2.39, price-to-sales of 177.32. Over the past 52 weeks the stock has ranged between $0.13 and $0.13, and currently trades at its 52-week high.
On profitability, E-therapeutics Plc generates a return on equity (ROE) of -40.58%, return on capital employed of -61.83%.
Official website: www.etherapeutics.co.uk